Please ensure Javascript is enabled for purposes of website accessibility

Why Bristol Myers Squibb Stock Fell Today

By Keith Speights - Apr 29, 2021 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker reported disappointing first-quarter results.

What happened

Shares of Bristol Myers Squibb (BMY 0.34%) were trading 4.9% lower as of 2:50 p.m. EDT on Thursday following the company's announcement of its first-quarter results before the market opened. 

So what

Bristol Myers Squibb missed analysts' Q1 estimates for both the top and bottom lines. Revenue rose 3% year over year to $11.1 billion, a little short of the consensus Wall Street estimate of $11.12 billion. Adjusted earnings were flat year over year at $4 billion, or $1.74 per share. The analysts' average estimate had been for adjusted earnings of $1.82 per share.

$1 bill folded into an arrow that points down

Image source: Getty Images.

Year-over-year comparisons weren't very impressive for one primary reason: Sales for several of Bristol Myers Squibb's drugs were artificially higher in the prior-year period because healthcare providers were stocking up on medication at the beginning of the COVID-19 pandemic in anticipation of potential supply chain issues. Of the company's blockbuster drugs, only one (cancer immunotherapy Yervoy) generated growth of more than 10% in Q1 2021.

Investors shouldn't be too pessimistic about the prospects for the big pharma stock, though. The impact of COVID-19 on its results will only be temporary, and Bristol Myers Squibb still has several drugs in its lineup that are capable of delivering stronger growth.

Now what

Bristol Myers Squibb projects full-year 2021 revenue growth in the high-single-digit percentages. Over the longer term, there are two key factors that will impact the company's growth. Revlimid will face limited-volume generic competition beginning in 2022. However, the company has newer drugs, including recently approved cell therapies Abecma (ide-cel) and Breyanzi (liso-cel), that could become blockbusters and potentially offset sales declines for Revlimid. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.22 (0.34%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.